Curanex Pharmaceuticals completed key manufacturing and toxicology milestones for its lead drug candidate Phyto-N, targeting ulcerative colitis, ahead of a planned IND submission to the FDA in Q4 2026. The company produced a GMP-compliant batch and finished a favorable dose-range toxicology study, supporting clinical trial readiness. Additionally, Curanex expanded its pipeline to include cancer cachexia, a condition with no FDA-approved treatments, aiming to explore new therapeutic opportunities. With $4 million in cash, the company is positioned to continue development and regulatory preparations toward clinical trials.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
